首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Truncation,modification, and optimization of MIG6segment 2 peptide to target lung cancer-related EGFR
Institution:1. Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou 318000, China;2. Linzi District Huangcheng Town Health Center, Zibo 255424, China;3. Department of Radiotherapy, Linzi District People’s Hospital, Zibo 255400, China;1. School of Life Sciences, Tianjin University, Tianjin 300072, China;2. Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, China;3. Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States;4. Institute of Virology and AIDS Research, First Hospital of Jilin University, 519 E Minzhu Ave, Changchun, Jilin Province 130061, China;1. Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan;2. Department of Orthopedic Surgery, National Rehabilitation Center for Children with Disabilities, Japan;3. Department of Orthopedic Surgery, Tokyo Metropolitan Kita Medical & Rehabilitation Center for the Handicapped, Japan;4. Center for Medical Genetics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan
Abstract:Human epidermal growth factor receptor (EGFR) plays a central role in the pathological progression and metastasis of lung cancer; the development and clinical application of therapeutic agents that target the receptor provide important insights for new lung cancer therapies. The tumor-suppressor protein MIG6 is a negative regulator of EGFR, which can bind at the activation interface of asymmetric dimer of EGFR kinase domains to disrupt dimerization and then inactivate the kinase (Zhang X. et al. Nature 2007, 450: 741–744). The protein adopts two separated segments, i.e. MIG6segment 1 and MIG6segment 2, to directly interact with EGFR. Here, computational modeling and analysis of the intermolecular interaction between EGFR kinase domain and MIG6segment 2 peptide revealed that the peptide is folded into a two-stranded β-sheet composed of β-strand 1 and β-strand 2; only the β-strand 2 can directly interact with EGFR activation loop, while leaving β-strand 1 apart from the kinase. A C-terminal island within the β-strand 2 is primarily responsible for peptide binding, which was truncated from the MIG6segment 2 and exhibited weak affinity to EGFR kinase domain. Structural and energetic analysis suggested that phosphorylation at residues Tyr394 and Tyr395 of truncated peptide can considerably improve EGFR affinity, and mutation of other residues can further optimize the peptide binding capability. Subsequently, three derivative versions of the truncated peptide, including phosphorylated and dephosphorylated peptides as well as a double-point mutant were synthesized and purified, and their affinities to the recombinant protein of human EGFR kinase domain were determined by fluorescence anisotropy titration. As expected theoretically, the dephosphorylated peptide has no observable binding to the kinase, and phosphorylation and mutation can confer low and moderate affinities to the peptide, respectively, suggesting a good consistence between the computational analysis and experimental assay.
Keywords:Human epidermal growth factor receptor  MIG6 protein  Peptide  Lung cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号